The Mikaela Naylon Give Kids a Chance Act was signed into law as part of the fiscal year 2026 federal appropriations package. It renews the priority review voucher program for rare pediatric diseases and allows the FDA to require combination studies of adult cancer drugs in children, incentivizing research in an area industry is often reluctant to invest in.
A 2026 study studied this question.